Go Pro
→ Why major institutions are piling into this digital asset now (From Awesomely) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$1.35
-8.5%		$4.41
$1.35
▼
$27.15
$25.79M1.6280,740 shs531,296 shs
InflaRx N.V. stock logo
IFRX
InflaRx
$2.23
-1.8%		$1.99
$0.80
▼
$2.95
$334.53M2.481.06 million shs610,417 shs
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$5.03
-1.4%		$4.41
$2.09
▼
$5.47
$212.15M1.22230,066 shs154,132 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-2.64%-1.67%-34.15%-87.86%-90.98%
InflaRx N.V. stock logo
IFRX
InflaRx
-6.20%+12.38%+34.32%-5.42%+127.00%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-4.49%+6.47%+22.30%+28.46%+130.77%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$1.35
-8.5%		$4.41
$1.35
▼
$27.15
$25.79M1.6280,740 shs531,296 shs
InflaRx N.V. stock logo
IFRX
InflaRx
$2.23
-1.8%		$1.99
$0.80
▼
$2.95
$334.53M2.481.06 million shs610,417 shs
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$5.03
-1.4%		$4.41
$2.09
▼
$5.47
$212.15M1.22230,066 shs154,132 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-2.64%-1.67%-34.15%-87.86%-90.98%
InflaRx N.V. stock logo
IFRX
InflaRx
-6.20%+12.38%+34.32%-5.42%+127.00%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-4.49%+6.47%+22.30%+28.46%+130.77%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
2.50
Moderate Buy$247.5018,233.33% Upside
InflaRx N.V. stock logo
IFRX
InflaRx
2.63
Moderate Buy$7.33228.85% Upside
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest IFRX, ORMP, and ENLV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/25/2026
InflaRx N.V. stock logo
IFRX
InflaRx
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/7/2026
InflaRx N.V. stock logo
IFRX
InflaRx
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$4.00 ➝ $6.00
7/27/2026
InflaRx N.V. stock logo
IFRX
InflaRx
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
7/21/2026
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
6/26/2026
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
6/24/2026
InflaRx N.V. stock logo
IFRX
InflaRx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/11/2026
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/A$122.21 per shareN/A
InflaRx N.V. stock logo
IFRX
InflaRx
$30K10,954.50N/AN/A$1.15 per share1.94
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$2M104.62$0.09 per share56.22$7.63 per share0.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$1.24B-$8.25N/AN/AN/AN/A248.08%206.39%8/28/2026 (Estimated)
InflaRx N.V. stock logo
IFRX
InflaRx
-$51.63M-$0.58N/AN/AN/AN/A-53.56%-43.02%11/9/2026 (Estimated)
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$64.05M$4.121.22N/AN/AN/A-5.17%-4.54%11/12/2026 (Estimated)

Latest IFRX, ORMP, and ENLV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/28/2026Q1 2026
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$0.31N/AN/AN/AN/AN/A
8/10/2026Q2 2026
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$0.43-$0.09-$0.52$1.84N/AN/A
8/7/2026Q2 2026
InflaRx N.V. stock logo
IFRX
InflaRx
-$0.0666-$0.11-$0.0434-$0.10$0.01 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/AN/A
InflaRx N.V. stock logo
IFRX
InflaRx
N/AN/AN/AN/AN/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$0.254.97%N/A6.07%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/A
193.24
193.24
InflaRx N.V. stock logo
IFRX
InflaRx
N/A
8.22
8.22
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
N/A
4.98
4.98

Institutional Ownership

CompanyInstitutional Ownership
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
1.02%
InflaRx N.V. stock logo
IFRX
InflaRx
42.39%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
12.73%

Insider Ownership

CompanyInsider Ownership
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
12.28%
InflaRx N.V. stock logo
IFRX
InflaRx
16.30%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
20.77%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
7017.49 million15.34 millionOptionable
InflaRx N.V. stock logo
IFRX
InflaRx
60147.37 million123.35 millionOptionable
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
1041.60 million32.96 millionOptionable

Recent News About These Companies

Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by Wall Street Zen to Buy Rating
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oramed-pharmaceuticals-nasdaqormp-upgraded-by-wall-street-zen-to-buy-rating-2026-08-15/
Oramed: Q2 Earnings Snapshot
August 11, 2026  |  chron.comhttps://www.chron.com/business/article/oramed-q2-earnings-snapshot-22382586.php
Oramed Pharmaceuticals (NASDAQ:ORMP) Releases Quarterly Earnings Results
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oramed-pharmaceuticals-nasdaqormp-releases-quarterly-earnings-results-2026-08-10/
Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Above 200 Day Moving Average - What's Next?
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oramed-pharmaceuticals-nasdaqormp-share-price-crosses-above-200-day-moving-average-whats-next-2026-08-06/
Oramed Pharmaceuticals (ORMP) Projected to Release Quarterly Earnings on Thursday
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oramed-pharmaceuticals-ormp-projected-to-release-quarterly-earnings-on-thursday-2026-08-06/
Insider Selling: Oramed Pharmaceuticals (NASDAQ:ORMP) CFO Sells $330,853.60 in Stock
July 3, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-ormp-insider-buying-and-selling-2026-07-03/
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
June 25, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/oramed-releases-letter-to-shareholders-highlighting-russell-20003000-index-inclusion-scilex-loan-repayment-strategic-portfolio-appreciation-and-a-strengthened-balance-sheet-302810903.html
ORMP: View inclusion in Russell indexes as positive that could raise awareness in investment community
June 18, 2026  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/ormp-view-inclusion-in-russell-indexes-as-positive-that-could-raise-awareness-in-investment-community/ar-AA25Z9Hc
Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
June 17, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/oramed-pharmaceuticals-to-join-russell-2000-and-russell-3000-indexes-302803049.html
ORMP: Strategically acquiring interests in medtech & technology companies
June 8, 2026  |  msn.comhttps://www.msn.com/en-us/news/technology/ormp-strategically-acquiring-interests-in-medtech-technology-companies/ar-AA257A8O
Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction
May 22, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4908089-oramed-pharmaceuticals-oral-insulin-drug-failure-pivot-and-new-strategic-investment-direction
Oramed Pharmaceuticals Inc.
May 18, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/Stock/ORMP/financials/cash-flow
Oramed Pharmaceuticals Delays Quarterly SEC Filing
May 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/oramed-pharmaceuticals-delays-quarterly-sec-filing?utm_source=marketbeat.com&utm_medium=referral
Oramed Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:ORMP
May 15, 2026  |  benzinga.comhttps://www.benzinga.com/quote/ORMP/earnings
Oramed Pharmaceuticals Incorporated
April 15, 2026  |  edition.cnn.comhttps://edition.cnn.com/markets/stocks/ORMP
Oramed Pharmaceuticals (ORMP) price target increased by 92.31% to 6.38
March 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/oramed-pharmaceuticals-ormp-price-target-increased-by-9231-to-638/ar-AA1Zzec8
Oramed: Q4 Earnings Snapshot
March 26, 2026  |  stamfordadvocate.comS
Lifeward Ltd.: Lifeward Successfully Closes on Strategic Partnership with Oramed
March 26, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/68042496-lifeward-ltd-lifeward-successfully-closes-on-strategic-partnership-with-oramed-399.htm
Lifeward Partners with Oramed to Enhance Biotech Portfolio and Drive Path to Profitability
March 13, 2026  |  quiverquant.comQ
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
March 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/13/3255419/32993/en/lifeward-receives-shareholder-approval-to-close-on-strategic-partnership-with-oramed-creating-diversified-biomedical-company.html
Oramed Pharmaceuticals Inc.: Oramed and Lifeward Announce Strategic Transaction
January 13, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-01/67423064-oramed-pharmaceuticals-inc-oramed-and-lifeward-announce-strategic-transaction-008.htm

New MarketBeat Followers Over Time

Media Sentiment Over Time

Enlivex Therapeutics stock logo

Enlivex Therapeutics NASDAQ:ENLV

$1.35 -0.13 (-8.47%)
As of 08/28/2026 04:00 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

InflaRx stock logo

InflaRx NASDAQ:IFRX

$2.23 -0.04 (-1.76%)
As of 08/28/2026 04:00 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Oramed Pharmaceuticals stock logo

Oramed Pharmaceuticals NASDAQ:ORMP

$5.03 -0.07 (-1.37%)
As of 08/28/2026 04:00 PM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas